Joseph E. Payne - 17 Dec 2025 Form 4 Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)

Reporting relationship: President and CEO, Director
Issuer ticker: ARCT
Reported as of: 17 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Dec 2025, 17:21:26 UTC
Prior SEC filing: 18 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Ilan Katz, attorney-in-fact

Key filing fact

Joseph E. Payne filed Form 4 for Arcturus Therapeutics Holdings Inc. (ARCT) on 19 Dec 2025.

Key facts

This page summarizes Joseph E. Payne's Form 4 filing for Arcturus Therapeutics Holdings Inc. (ARCT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Dec 2025, 17:21.

Change

Previous filing in this sequence was filed on 18 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001727315 Primary reporting owner

Payne Joseph E

Relationship: President and CEO, Director
Address: C/O ARCTURUS THERAPEUTICS HOLDINGS INC., 10285 SCIENCE CENTER DRIVE, SAN DIEGO
Signature: /s/ Ilan Katz, attorney-in-fact
Signature date: 19 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARCT transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +175,000
Change %
Price: $0.000000
Shares after: 175,000
Date: 17 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 175,000
Exercise price: $6.52
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

Footnote F2

The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.